PCM
LKFT

Prelude Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Prelude Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$579K Hold
19,305
– – 0.04% 453
2025
Q4 		$631K Sell
19,305
-22
-0.1% -$710 0.05% 449
2025
Q3 		$669K Buy
19,327
+22
+0.1% +$704 0.05% 419
2025
Q2 		$540K Hold
19,305
– – 0.05% 415
2025
Q1 		$485K Buy
19,305
+170
+0.9% +$4.3K 0.04% 524
2024
Q4 		$526K Hold
19,135
– – 0.03% 580
2024
Q3 		$551K Buy
19,135
+10,503
+122% +$286K 0.03% 588
2024
Q2 		$214K Buy
+8,632
New +$245K 0.01% 968
2024
Q1 		– Sell
-6,684
Closed -$272K – 1390
2023
Q4 		$272K Buy
6,684
+4
+0.1% +$147 0.02% 782
2023
Q3 		$231K Buy
6,680
+45
+0.7% +$1.75K 0.02% 818
2023
Q2 		$270K Hold
6,635
– – 0.02% 697
2023
Q1 		$256K Sell
6,635
-3,990
-38% -$164K 0.02% 726
2022
Q4 		$472K Sell
10,625
-4,027
-27% -$169K 0.02% 594
2022
Q3 		$625K Buy
14,652
+12
+0.1% +$615 0.02% 564
2022
Q2 		$817K Sell
14,640
-15,120
-51% -$896K 0.02% 600
2022
Q1 		$1.85M Buy
29,760
+7,255
+32% +$444K 0.05% 370
2021
Q4 		$1.24M Buy
+22,505
New +$1.17M 0.03% 507
2017
Q3 		– Sell
-468
Closed -$36K – 1728
2017
Q2 		$36K Buy
+468
New +$39.4K ﹤0.01% 1096
2016
Q4 		– Sell
-2,412
Closed -$156K – 1637
2016
Q3 		$156K Buy
+2,412
New +$136K 0.02% 645
2015
Q3 		– Sell
-300
Closed -$15K – 1589
2015
Q2 		$15K Buy
+300
New +$15.9K ﹤0.01% 1504

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's LKFT Position: Q1 2026 in Review

Prelude Capital Management held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q1 2026 at 19,305 shares worth $579K. The position accounts for 0.04% of the portfolio, ranked #453.

Prelude Capital Management first reported a position in LKFT in Q2 2015 and has held it in 20 quarters since. The position peaked at $1.85M in Q1 2022. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Prelude Capital Management held 19,305 shares of Lakefront Biotherapeutics American Depositary Shares worth $579K as of Q1 2026.
  • Prelude Capital Management left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q1 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #453 holding.
  • Prelude Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 20 quarters since.
  • Prelude Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.85M in Q1 2022.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.